Impact of SARS-Cov-2 infection in patients with hypertrophic cardiomyopathy : results of an international multicentre registry
Gimeno-Blanes, Juan R (Center for Biomedical Network Research on Cardiovascular Diseases (CIBERCV))
Olivotto, Iacopo (Careggi University Hospital (Florència, Itàlia))
Rodríguez, Ana Isabel (European Reference Networks for rare, low prevalence and complex diseases of the heart (ERN GUARD-Heart))
Ho, Carolyn Y. (Brigham and Women's Hospital (Boston, Estats Units d'Amèrica))
Fernández, Adrián (Favaloro Foundation University Hospital)
Quiroga, Alejandro (Favaloro Foundation University Hospital)
Espinosa, Mari Angeles (Hospital General Universitario Gregorio Marañón)
Gómez-González, Cristina (Hospital General Universitario Gregorio Marañón)
Robledo, María (Hospital Universitario Araba (Txagorritxu))
Tojal-Sierra, Lucas (Hospital Universitario Araba (Txagorritxu))
Day, Sharlene M. (Hospital of the University of Pennsylvania)
Owens, Anjali (Hospital of the University of Pennsylvania)
Barriales-Villa, Roberto (Complejo Hospitalario Universitario de A Coruña)
Larrañaga, Jose María (Complejo Hospitalario Universitario de A Coruña)
Rodriguez-Palomares, Jose F (Hospital Universitari Vall d'Hebron)
González-del-Hoyo, Maribel (Hospital Universitari Vall d'Hebron)
Piqueras-Flores, Jesús (Hospital General Universitario de Ciudad Real)
Reza, Nosheen (Hospital of the University of Pennsylvania)
Chumakova, Olga (Municipal Clinical Hospital #17)
Ashley, Euan A. (Stanford University Medical Center)
Parikh, Victoria (Stanford University Medical Center)
Wheeler, Matthew (Stanford University Medical Center)
Jacoby, Daniel (Yale New Haven Hospital)
Pereira, Alexandre C. (Hospital das Clinicas da Univerisidade de Sao Paulo)
Saberi, Sara (University of Michigan Hospital)
Helms, Adam S. (University of Michigan Hospital)
Villacorta, Eduardo (Universidad de Salamanca)
Gallego-Delgado, María (Universidad de Salamanca)
de Castro, Daniel (Hospital Universitario Puerta de Hierro Majadahonda (Madrid))
Domınguez, Fernando (Hospital Universitario Puerta de Hierro Majadahonda (Madrid))
Ripoll-Vera, Tomás (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears))
Zorio, Esther (Hospital Universitari i Politècnic La Fe (València))
Sánchez-Martínez, José Carlos (Hospital Universitari i Politècnic La Fe (València))
García-Álvarez, Ana (Hospital Clínic i Provincial de Barcelona)
Arbelo, Elena (Hospital Clínic i Provincial de Barcelona)
Mogollón, María Victoria (Hospital San Pedro de Alcántara)
Fuentes-Cañamero, María Eugenia (Badajoz University Hospital)
Grande, Elias (Dilemma Solution S.L)
Peña, Carlos (Dilemma Solution S.L)
Monserrat, Lorenzo (Dilemma Solution S.L)
Lakdawala, Neal K. (Brigham and Women's Hospital (Boston, Estats Units d'Amèrica))
Universitat Autònoma de Barcelona

Fecha:	2022
Resumen:	To describe the natural history of SARS-CoV-2 infection in patients with hypertrophic cardiomyopathy (HCM) compared with a control group and to identify predictors of adverse events. Three hundred and five patients [age 56. 6 ± 16. 9 years old, 191 (62. 6%) male patients] with HCM and SARS-Cov-2 infection were enrolled. The control group consisted of 91 131 infected individuals. Endpoints were (i) SARS-CoV-2 related mortality and (ii) severe clinical course [death or intensive care unit (ICU) admission]. New onset of atrial fibrillation, ventricular arrhythmias, shock, stroke, and cardiac arrest were also recorded. Sixty-nine (22. 9%) HCM patients were hospitalized for non-ICU level care, and 21 (7. 0%) required ICU care. Seventeen (5. 6%) died: eight (2. 6%) of respiratory failure, four (1. 3%) of heart failure, two (0. 7%) suddenly, and three (1. 0%) due to other SARS-CoV-2-related complications. Covariates associated with mortality in the multivariable were age {odds ratio (OR) per 10 year increase 2. 25 [95% confidence interval (CI): 1. 12-4. 51], P = 0. 0229}, baseline New York Heart Association class [OR per one-unit increase 4. 01 (95%CI: 1. 75-9. 20), P = 0. 0011], presence of left ventricular outflow tract obstruction [OR 5. 59 (95%CI: 1. 16-26. 92), P = 0. 0317], and left ventricular systolic impairment [OR 7. 72 (95%CI: 1. 20-49. 79), P = 0. 0316]. Controlling for age and sex and comparing HCM patients with a community-based SARS-CoV-2 cohort, the presence of HCM was associated with a borderline significant increased risk of mortality OR 1. 70 (95%CI: 0. 98-2. 91, P = 0. 0600). Over one-fourth of HCM patients infected with SARS-Cov-2 required hospitalization, including 6% in an ICU setting. Age and cardiac features related to HCM, including baseline functional class, left ventricular outflow tract obstruction, and systolic impairment, conveyed increased risk of mortality.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	COVID-19 ; Heart failure ; Hypertrophic cardiomyopathy ; Prognosis ; Registry ; SARS-CoV-2 infection
Publicado en:	ESC Heart Failure, Vol. 9 (june 2022) , p. 2189-2198, ISSN 2055-5822

DOI: 10.1002/ehf2.13964
PMID: 36255281

10 p, 1.6 MB

El registro aparece en las colecciones:
Artículos > Artículos de investigación
Artículos > Artículos publicados